Empower Pharmacy FDA Warning Letter: What It Means for Other Pharmacies, Prescribers, Clinics, and Labs
FDA's Empower letter targets prescriber documentation for compounded GLP-1s. On September 18, 2026, FDA issued a warning letter to Empower Pharmacy's Houston 503A pharmacy, one of the largest compounders in the country and a major supplier to telehealth weight-loss platforms. FDA found that Empower's semaglutide and tirzepatide combination products are essentially copies of approved drugs, making them unapproved, misbranded, and adulterated. It found prescriber significant difference statements that appear repeated verbatim across many records, and it warned that third-party technology platforms offering prescribers pre-selected menu options call the individualized nature of those statements into question. The records FDA reviewed also identify the prescribers, clinics, and platforms behind those orders. The letter is addressed to the founder and CEO. It is the second warning letter to the same facility in less than 18 months.
Overview: Compounded GLP-1 Enforcement Moves From Marketing to Prescription Records
The Empower letter addresses the prescription documentation behind high-volume GLP-1 compounding. Section 503A allows a pharmacy to compound a copy of an approved drug only when the prescriber determines that a change produces a significant difference for an identified patient. FDA found orders with no determination, orders with determinations that appear pre-generated, and volume that made the stated differences look pretextual.
The finding reaches past Empower. The statute assigns the determination to the prescriber, and the letter identifies telehealth technology as a possible source of the repeated wording. Empower's prescription records identify the prescriber, clinic, and platform behind each order. Those records give investigators a starting point for inquiries into other pharmacies, prescribers, clinics, and the laboratories that bill for testing in GLP-1 programs.
Seizure, injunction, and criminal prosecution are the FDCA remedies that follow a warning letter. At DOJ, they now belong to the Civil Division's Enforcement & Affirmative Litigation Branch and the Fraud Section's Health and Safety Unit. Where federal or commercial payers or per-prescription payments are involved, health care fraud, False Claims Act, and Anti-Kickback theories may follow.
FDA's compounded GLP-1 enforcement in the first half of 2026 focused on marketing. On March 3, it announced 30 warning letters to telehealth companies for claims implying that compounded GLP-1s are the same as approved drugs and for branding that obscured who compounded the product. A second wave of 25 letters followed in June. We analyzed those letters, and the criminal and False Claims Act exposure they created, in our earlier review of FDA warning letters on compounded semaglutide and telehealth. The Empower letter addresses a different issue: the prescriptions themselves.
This letter is based on an inspection. FDA investigators were inside Empower's Houston pharmacy from November 3 to 14, 2025. They collected production records and prescriptions and compared the prescriptions to one another. The resulting findings concern what prescribers sign, in addition to what telehealth companies advertise.
The letter follows FDA's February 6, 2026 announcement that it would take decisive steps against mass-marketed compounded GLP-1s, including restrictions on the active ingredients used to make them. DOJ has also reorganized its FDCA enforcement units and consolidated its fraud prosecutors in a new National Fraud Enforcement Division. Additional inspection-based letters to compounders are likely.
What FDA Found at Empower
The warning letter is addressed to Arta Shaun Noorian, Empower's founder and chief executive officer. It follows the November 2025 inspection, a Form FDA 483 issued November 14, 2025, and three written responses from Empower dated December 8, 2025, March 18, 2026, and April 30, 2026. FDA reviewed all three responses before issuing the letter.
Three products carry the essentially-copy finding: tirzepatide/niacinamide in 4 mL (17/2 mg/mL) and 2.5 mL (8/2 mg/mL) presentations, and semaglutide/cyanocobalamin in 1 mL (5/0.5 mg/mL). FDA listed monthly order counts for each from July through October 2025. The counts are redacted. According to the letter, FDA's enforcement discretion for 503A pharmacies compounding copies ended March 5, 2025 for tirzepatide and April 24, 2025 for semaglutide. Every month FDA counted falls after both dates.
The Added-Vitamin Workaround Fails on Volume
After the shortages ended, many compounders added a second ingredient, such as niacinamide in tirzepatide or vitamin B12 in semaglutide. The premise was that a product with a different ingredient list is not essentially a copy. FDA rejected that premise on these facts, writing that the volume of Empower's production suggests the differences between its products and the approved drugs are pretextual.
The letter does not adopt a categorical rule on added ingredients. Its reasoning rests on volume. Section 503A permits compounding a copy only where the prescriber makes a change for an identified individual patient. A formulation ordered in the quantities FDA described is difficult to reconcile with individual determinations.
Three Categories of Prescription Evidence
FDA identified three categories of evidence behind the essentially-copy finding. The first is orders and prescriptions with no prescriber determination of significant difference. The second is orders with purported determinations that appear repeated verbatim across many records, which FDA said suggests they may be pre-generated for the prescriber to select instead of written for an identified patient. The third is the volume of particular products compounded and orders filled.
The letter also describes one way pre-generated statements may be produced:
“…third-party technology platforms that provide prescribers with pre-selected menu options for choosing a statement of significant difference…”
FDA Warning Letter 738238 to Empower Pharmacy (Sept. 18, 2026)FDA wrote that prescriptions generated this way call the individualized nature of the prescriber's determination into question. Although the letter is addressed to a pharmacy, that passage concerns the telehealth prescribing process, including patient intake, e-prescribing integration, and the options presented to the prescriber.
The Sterility Findings, Repeated
The second half of the letter concerns sterile processing. FDA found insanitary conditions under 21 U.S.C. § 351(a)(2)(A). Smoke studies did not demonstrate unidirectional airflow in the ISO 5 area under dynamic conditions. Media fills were not performed under the most challenging or stressful conditions. For the ineligible products, FDA added five CGMP violations under 21 CFR Part 211, covering equipment maintenance for aseptic conditions, validation of aseptic and sterilization processes, quality unit oversight, environmental monitoring, and production controls.
FDA also found parts of Empower's 483 responses deficient or unsupported. The April 2026 smoke study remained in post-execution review and had not been finalized. The January 2026 media fill summary reported no contamination in any vial, but the vial counts in the underlying records did not match the summary. Several entries were marked N/A with no definition. Some media fill results had been transcribed onto a new form revision because the originals were recorded on the wrong form, with no clear audit trail showing who authorized the change or why.
FDA has warned this facility before. On April 2, 2025, FDA issued Warning Letter 700964 to the same Houston address. That letter went to Empower's Director of Quality. One of its findings was that media fills were not performed under the most challenging or stressful conditions. The September 2026 letter repeats that finding word for word and is addressed to the CEO. Empower's separate 503B outsourcing facility received its own warning letters in October 2021 and April 2025.
A finding repeated after written notice is the type of evidence DOJ uses to show a danger of continuing violations, which is the standard for an injunction. The letter also states that the insanitary conditions provision applies whether or not a drug meets 503A. The sterility findings therefore stand independently of any defense of the prescriptions.
The Evidentiary Hook: Templated Significant Difference Statements
Section 503A exempts a compounded drug from FDA approval, CGMP, and adequate-directions labeling only when the drug meets the statute's conditions. One condition bars compounding, regularly or in inordinate amounts, drugs that are essentially copies of a commercially available product. 21 U.S.C. § 353a(b)(1)(D). The exception is narrow. A compounded drug is not a copy if a change made for an identified individual patient produces, for that patient, a significant difference as determined by the prescribing practitioner. § 353a(b)(2).
Industry often calls this the medical necessity statement. The statutory term is significant difference, and the statute assigns it to the prescriber. FDA's 2018 guidance on essentially copies explains how the agency applies the provision and expects compounders to keep records supporting compliance. State boards apply similar rules. The Massachusetts Board of Pharmacy, for example, states that a price difference is not a significant difference.
As a result, the pharmacy's exemption depends on the prescriber's statement, and that statement is the first document the government will examine.
How Investigators Use Templated Statements
Determinations written for individual patients tend to vary. Pre-written menu options produce identical text across unrelated patients, which allows investigators to review a platform's entire prescription population through data analysis.
Prescribing platforms typically log which option was selected, whether it was a default, how long the prescriber spent on the chart, and how many approvals the prescriber completed in a given period. Internal records may show who drafted the menu language, who approved it, and whether compliance staff raised concerns. FDA identified the pattern from pharmacy records alone. Platform data obtained by subpoena would show how the statements were generated.
A single template can appear on every prescription a platform generates. If the government proves the template was a formality, its theory can reach the entire book of business.
The Limits of Template Evidence
Repeated language can have legitimate explanations. Many patients share the same clinical reason for a compounded formulation, such as a dose or titration step the approved pens do not offer. A structured field can record a real determination efficiently. Section 503A prescribes no documentation format. The 2018 guidance is nonbinding. FDA's own letter speaks in terms of what the records appear to show and what they suggest. The dispute turns on whether a prescriber evaluated the identified patient and made the determination. That question is answered by the patient chart and the platform's audit logs.
After the Warning Letter: Where Enforcement Goes Next
FDA treats warning letters as informal and advisory. They provide notice before FDA refers a matter to DOJ for court action. The Empower letter warns that failure to correct may result in legal action without further notice, including seizure and injunction.
The DOJ components that bring those actions have changed. The Consumer Protection Branch, which handled civil and criminal FDCA cases for decades, was dissolved in 2025. Civil FDCA enforcement, including seizure and injunction, now sits in the Civil Division's Enforcement & Affirmative Litigation Branch. Criminal FDCA enforcement moved to the Fraud Section's Health and Safety Unit, which prosecutes the distribution of adulterated and misbranded drugs, failures to maintain sanitary facilities, and concealment of safety information from FDA. Health care fraud and kickback cases run through the Health Care Fraud Unit and its Strike Forces. A single set of facts can support matters in all three.
In investigations of federal health care offenses, DOJ can issue administrative subpoenas under 18 U.S.C. § 3486. Civil investigative demands, grand jury subpoenas, and search warrants reach the same records.
Seizure and Injunction
Under 21 U.S.C. § 334, the government can seize adulterated or misbranded drugs. Under § 332, it can enjoin violations of § 331. Courts apply a lenient standard. As a federal court explained in granting a preliminary injunction in United States v. 2035 Inc., the government need only show that the statute applies and that a cognizable danger of recurrent violations exists. A finding repeated at the same facility after a prior warning letter is evidence of recurrence.
DOJ has obtained this relief against Texas compounders before. In 2019, the Southern District of Texas entered a consent decree against Pharm D Solutions and its owners that halted sterile compounding until FDA confirmed compliance. The same year, the Northern District of Texas entered a permanent injunction against Guardian Pharmacy Services and its owner. DOJ's complaint there alleged insanitary conditions. It also alleged that drugs distributed without patient-specific prescriptions were misbranded and unapproved. That second theory is the 503A-conditions theory at the center of the Empower letter. Both decrees bound the owners individually.
Criminal Exposure and Intent to Mislead FDA
Introducing an unapproved, misbranded, or adulterated drug into interstate commerce is a prohibited act under 21 U.S.C. § 331. Under § 333(a), it is a strict-liability misdemeanor, and a felony when committed with intent to defraud or mislead. Our earlier article covered the responsible corporate officer doctrine and the path from misdemeanor to felony.
Templated documentation raises an additional intent issue. Courts have held that the intent element of § 333(a)(2) can be met by intent to defraud or mislead a government agency, including FDA. See United States v. Bradshaw, 840 F.2d 871 (11th Cir. 1988). A significant difference statement exists to satisfy an exemption FDA administers. If the government proves the statements were generated to make ineligible drugs appear eligible, it will argue they were written to mislead FDA.
Two other statutes are relevant. The defraud clause of 18 U.S.C. § 371 reaches agreements to obstruct a lawful government function by deceit, the rule of Hammerschmidt v. United States, 265 U.S. 182 (1924). The government could allege that a pharmacy, a platform, and a prescriber network that coordinated on menu language were parties to such an agreement. And 18 U.S.C. § 1519 punishes altering or falsifying records with intent to impede a federal investigation. FDA's criticism of Empower's transcribed media fill records shows that the agency scrutinizes documentation changes made after an inspection.
Payers, Kickbacks, and the Done Global Model
Our earlier article explained how False Claims Act and Anti-Kickback theories attach to compounded GLP-1 programs. Templated clinical statements can supply evidence for those theories, as standardized representations have in other telehealth prosecutions.
Done Global is an example. In July 2026, the company's founder was sentenced to 72 months and its clinical president to 24 months. DOJ's case rested on the company's technology platform, compensation structure, and clinical protocols. It included prior authorization requests that told insurers Done followed DSM-5 diagnostic criteria and used drug screens, which DOJ alleged were false. A GLP-1 case built on significant difference statements would follow the same structure.
Compounded GLP-1s themselves are rarely billable to Medicare. The Part D statute excludes drugs used for weight loss, 42 U.S.C. § 1395w-102(e)(2)(A), and CMS does not treat bulk active pharmaceutical ingredients, the starting material for most compounded semaglutide and tirzepatide, as Part D drugs. Medicare Prescription Drug Benefit Manual, ch. 6, § 10.4. The Medicare GLP-1 Bridge, which began July 1, 2026, covers weight-loss use of specified FDA-approved products only.
Payer exposure in these programs usually runs through what surrounds the compounded drug: telehealth visits and lab work billed to Medicare, Medicaid, TRICARE, or commercial insurers; branded GLP-1 prescriptions written through the same platform; and any claim that presents a compounded product as a covered drug. In those claims, the prescriber's documentation, including templated clinical statements, becomes part of the supporting record. The health care fraud statute, 18 U.S.C. § 1347, reaches private insurers because it covers any health care benefit program as defined in 18 U.S.C. § 24. The False Claims Act reaches federal payers. Per-prescription payments among pharmacies, platforms, and prescribers bring the Anti-Kickback Statute into play wherever federal program business is part of the mix. HHS-OIG's Special Fraud Alert on telemedicine arrangements lists the characteristics investigators look for, including limited patient interaction and practitioner compensation tied to the volume of items ordered.
Cash-pay programs also carry exposure. Many states have anti-kickback and fee-splitting statutes that apply regardless of payer. DOJ has also used the Travel Act, 18 U.S.C. § 1952, to charge schemes built on violations of state commercial bribery laws.
Where the Investigation Goes Next: Other Pharmacies, Prescribers, Clinics, and Labs
The Empower letter names one pharmacy. The records behind it name many more parties. Each order Empower filled identifies a prescriber, a patient, a shipping address, and, for telehealth orders, the platform that transmitted it. The significant difference text on those orders can be sorted by prescriber and by platform. That sort shows who supplied the repeated language, how often, and through which channels.
Compounding enforcement has moved this way before. DOJ's TRICARE compounding prosecutions began with pharmacies and extended to the physicians, nurse practitioners, marketers, and owners connected to them. Cash-pay GLP-1 programs involve a different payer, which changes some of the statutes. The investigative method is the same.
Other Compounding Pharmacies and Suppliers
Telehealth platforms often route prescriptions to more than one pharmacy. Menu language built into a platform would appear on orders at every pharmacy receiving that platform's prescriptions, so identical text at a second pharmacy links the two inquiries. The letter also gives FDA investigators a template for inspecting other 503A pharmacies that produce the same tirzepatide and semaglutide combinations: order volume by formulation, significant difference text across records, and ISO 5 and media fill data. Pharmacy purchasing records extend the inquiry upstream to active ingredient suppliers, a focus of FDA's February 2026 announcement on restricting GLP-1 ingredients.
Prescribers
Sorting orders by prescriber shows approval volume, the states where a prescriber's patients live, the time between approvals, and whether a prescriber's statements ever varied. DOJ has used those facts against prescribers in compounding cases. In the Northern District of Oklahoma, a pharmacy owner was sentenced in a scheme in which physicians received pre-printed prescription pads listing compounding formula choices, checked a box, and faxed the form to affiliated pharmacies. In the Eastern District of Arkansas, prosecutors alleged that a prescriber used a phone app to sign batches of pre-filled prescriptions, including eight within three minutes. In the Southern District of Mississippi, a physician was convicted at trial on evidence that he prescribed compounded drugs to patients he had not examined and falsified records in response to a TRICARE audit.
A pre-selected significant difference statement in an e-prescribing menu is the electronic equivalent of the check-box pad. The prescribers who selected it are identifiable from the pharmacy's records alone.
Clinics and Med Spas
Pharmacy shipping records show which clinics received product and in what quantities. Shipments to one clinic address under many patient names, or in quantities that resemble office stock, raise the patient-specific prescription problem at the center of DOJ's case against Guardian Pharmacy Services. Clinics whose prescribers used pharmacy-supplied or platform-supplied statements share the documentation problem. Clinics that relabeled vials under their own names face the labeling theory FDA applied in its 2026 telehealth letters.
Clinical Laboratories
Laboratories are often where federal and insurance dollars enter an otherwise cash-pay GLP-1 program. Many telehealth weight-loss programs order baseline or monitoring lab work, and those tests can be billed to Medicare, Medicaid, or commercial insurers even when the drug is not. Medicare generally requires diagnostic tests to be ordered by the physician or practitioner who treats the beneficiary and uses the results in the beneficiary's care. 42 CFR 410.32(a). Tests ordered through a templated intake with no genuine treating relationship fit the model DOJ used in its telemedicine genetic testing prosecutions. Referral payments add separate risk. The Eliminating Kickbacks in Recovery Act, 18 U.S.C. § 220, applies to laboratories and reaches private insurers as well as federal programs.
A warning letter to one high-volume pharmacy therefore works as a list of the prescribers, clinics, platforms, labs, and suppliers that did business with it. The questions FDA asked about Empower's orders can be asked of every party on that list.
Who Is Exposed After the Empower Letter
Although the letter is addressed to one pharmacy, the evidence it describes involves every participant in the compounded GLP-1 supply chain.
| Participant | What Investigators Will Examine | Primary Exposure |
|---|---|---|
| 503A compounding pharmacies | Order volume by formulation; significant difference text across records; ISO 5 smoke studies and media fill data; prior 483s and warning letters | Seizure, injunction, FDCA misdemeanor and felony counts, state board action |
| 503B outsourcing facilities | Essentially-copy limits under 503B; CGMP compliance; distribution to clinics and platforms | Seizure, injunction, loss of 503B status, FDCA counts |
| Telehealth platforms and e-prescribing vendors | Menu design and default selections; authorship of the statement language; click, session, and approval-time logs; pharmacy payment terms | Aiding and abetting, conspiracy, health care fraud where payers are involved, kickback theories |
| Prescribers | Approvals per hour; whether the chart supports the selected statement; compensation per consult or per script | Licensure, false statement and health care fraud charges, conspiracy |
| Med spas and clinics | Patient-specific prescriptions versus office stock; relabeled vials; sourcing from 503A or 503B | Misbranding, state board action, manufacturer litigation |
| Clinical laboratories | Tests ordered through telehealth intake; documentation of a treating relationship; per-test payments to platforms, marketers, or prescribers | Health care fraud, False Claims Act, EKRA, Anti-Kickback Statute |
| Founders, executives, and investors | Board materials; compliance warnings; the response to the March and June 2026 letters | Responsible corporate officer liability; notice evidence supporting felony intent |
Where the Defense Begins
Every matter that grows from this letter runs on parallel tracks: FDA's regulatory review, DOJ civil enforcement, DOJ criminal investigation, state pharmacy and medical boards, and manufacturer litigation that generates its own discovery. A decision on one track affects the others.
The 15 working day response is the first of those decisions. It is a written statement to a federal agency. It is discoverable, it is read by the agency that makes criminal referrals, and false statements in it are chargeable under 18 U.S.C. § 1001. Empower's three 483 responses are now quoted and criticized in a public letter.
The second is record integrity. Prescription records, platform logs, media fill data, and internal communications about menu design are the core evidence. Records altered after notice can create obstruction exposure independent of the underlying conduct.
The third is the substantive defense, which is built patient by patient. The statute gives the determination to the prescriber and prescribes no format. A pharmacy's reliance on a facially complete prescription is a factual question. Repeated wording can reflect repeated clinical facts. A defense built on charts, prescriber testimony, and platform data showing individualized evaluation can contest FDA's inference. Those records must exist before the investigation reaches them.
Armstrong & Bradylyons PLLC: Telehealth, Anti-Kickback, and GLP-1 Defense
Armstrong & Bradylyons PLLC defends compounding pharmacies, telehealth startups, prescribers, and the founders and executives who run them in FDA, DOJ, and False Claims Act matters involving compounded GLP-1s and peptides. The work runs through the firm's peptide and GLP-1 fraud defense, telemedicine fraud defense, and healthcare fraud and Anti-Kickback Statute defense practices. For the clinics at the end of the supply chain, the firm's med spa and aesthetic medicine fraud defense practice defends owners, medical directors, and nurse injectors facing FDA, DOJ, and state board scrutiny over compounded GLP-1s and other injectables.
The firm's attorneys have represented executives at a leading peptides distributor in a DOJ investigation into research use only representations; executives in a joint DOJ and FDA Office of Criminal Investigations investigation into a leading pharmaceutical company; the founder and the CEO of healthcare startups in DOJ investigations, including one involving approximately $50 million in Medicare claims; and a nurse practitioner and a physician assistant in DEA proceedings arising from prescribing at a leading national testosterone clinic.
Scott Armstrong served as Director of DOJ's Appalachian Regional Prescription Opioid Strike Force and as an Assistant Chief in the Fraud Section. At DOJ, he was lead counsel in a $126 million fraud scheme involving compounded medications, with charged conduct by physicians, pharmacists, executives, and marketers. He has tried sixteen federal jury trials, including nine healthcare fraud trials, and served as lead counsel in cases totaling over $600 million in false claims.
Drew Bradylyons served as an Assistant Chief in the Fraud Section's Health Care Fraud Unit, where he supervised the Florida Strike Force, and as Chief of the Financial Crimes and Public Corruption Unit at the U.S. Attorney's Office for the Eastern District of Virginia. He oversaw a nationwide enforcement action involving medically unnecessary durable medical equipment prescribed through telehealth, with more than $100 million in losses, and supervised parallel civil, criminal, and administrative proceedings involving more than $1 billion in claims.
At DOJ, the firm's attorneys also prosecuted a $1 billion scheme involving a telemedicine platform that generated false doctors' orders used to bill Medicare. The firm's attorneys have tried 25 federal jury trials, including 17 healthcare fraud trials involving over $2.8 billion in alleged false claims. The firm is based in Washington, D.C. and handles matters in every federal district.
Frequently Asked Questions
What did FDA's warning letter to Empower Pharmacy find?
FDA found that Empower's Houston 503A pharmacy compounded GLP-1 products that are essentially copies of approved semaglutide and tirzepatide drugs, regularly or in inordinate amounts. Warning Letter 738238, issued September 18, 2026, followed a November 2025 inspection and is addressed to Empower's founder and CEO. The cited products are two tirzepatide/niacinamide formulations and one semaglutide/cyanocobalamin formulation.
Because those products fall outside Section 503A, FDA treats them as unapproved new drugs under 21 U.S.C. § 355(a), misbranded under § 352(f)(1), and adulterated under § 351(a)(2)(B) based on five CGMP violations. FDA separately found insanitary conditions under § 351(a)(2)(A), including inadequate ISO 5 smoke studies and media fills not run under worst-case conditions. That charge applies regardless of 503A status. The letter also criticizes prescriber statements that appear repeated verbatim across many records. Empower has 15 working days to respond. FDA reserved seizure and injunction.
Is compounded tirzepatide or semaglutide with B12 legal?
Not automatically. Adding vitamin B12 or niacinamide to a GLP-1 does not by itself take the product outside the Section 503A ban on compounding essentially copies of approved drugs. In the Empower letter, FDA found that the volume of these combination products suggests the differences from the approved drugs are pretextual. FDA's enforcement discretion for 503A copies ended March 5, 2025 for tirzepatide and April 24, 2025 for semaglutide. Every order FDA counted came after both dates.
A compounded version remains lawful only when the prescriber determines that a change made for an identified individual patient produces a significant difference for that patient, 21 U.S.C. § 353a(b)(2), and the pharmacy meets the other 503A conditions. The letter stops short of a categorical rule on additives. It does make clear that a standard formulation ordered at scale, supported by standardized justifications, is the pattern FDA will treat as a copy.
What is a significant difference statement for compounded GLP-1s?
It is the prescriber's determination that a change in a compounded drug produces a clinically meaningful difference for a specific patient compared with the approved product. Section 503A generally bars compounding essentially copies of commercially available drugs regularly or in inordinate amounts. 21 U.S.C. § 353a(b)(1)(D). The statute exempts a drug when a change made for an identified individual patient produces, for that patient, a significant difference as determined by the prescribing practitioner. § 353a(b)(2).
Pharmacies and telehealth platforms often call this the medical necessity statement. It belongs to the prescriber. It must relate to an identified patient. It must describe a real clinical difference. FDA's 2018 guidance on essentially copies explains how the agency applies the provision and expects compounders to keep supporting records. State boards follow similar rules. The Massachusetts Board of Pharmacy states that a lower price is not a significant difference.
Why do templated prescriber statements create legal risk for pharmacies?
Templated statements can put a pharmacy's 503A exemption at risk for every prescription that uses them. In the Empower letter, FDA identified significant difference determinations that appear repeated verbatim across many records and said they may be pre-generated for prescribers to select instead of written for an identified patient. FDA added that third-party technology platforms offering pre-selected menu options call the individualized nature of those determinations into question.
A template produces identical records across unrelated patients, which lets investigators analyze an entire prescription population with data. Platform logs then show which option was chosen, whether it was a default, how long the prescriber spent on the chart, and who wrote the menu language. Repeated wording is not conclusive. Patients can share a clinical reason, and Section 503A prescribes no documentation format. The dispute turns on whether a prescriber evaluated each patient and made the determination. Patient charts and platform audit logs are the evidence on that question.
What happens after an FDA warning letter to a compounding pharmacy?
FDA can refer the matter to DOJ for seizure, injunction, or criminal prosecution without further notice. Seizure under 21 U.S.C. § 334 removes adulterated or misbranded drugs from the market. An injunction under § 332 can halt operations. The government generally must show that the statute applies and that a cognizable danger of recurrent violations exists. Compounding consent decrees usually stop sterile production until FDA confirms compliance and bind owners personally, as in the 2019 decrees against Pharm D Solutions and Guardian Pharmacy Services in Texas.
DOJ restructured this work in 2025 when it dissolved the Consumer Protection Branch. Civil FDCA cases now belong to the Civil Division's Enforcement & Affirmative Litigation Branch. Criminal FDCA cases belong to the Fraud Section's Health and Safety Unit. The pharmacy's 15 working day response is itself a written statement to a federal agency. It is discoverable later and subject to 18 U.S.C. § 1001.
Will other pharmacies and prescribers be investigated after the Empower letter?
They can be, and the evidence to start those inquiries already exists. Empower's prescription records identify the prescriber, patient, shipping address, and transmitting platform for each order. The significant difference text on those orders can be sorted by prescriber and platform, which shows who supplied the repeated language. A platform that sent the same menu language to several pharmacies created the same pattern at each of them.
Compounding investigations have followed this path before. In the TRICARE compounding cases, DOJ moved from pharmacies to the physicians and nurse practitioners who signed their prescriptions. Those cases included prescribers who checked boxes on pre-printed formula pads and a prescriber alleged to have signed batches of pre-filled prescriptions on a phone app within minutes. Cash-pay GLP-1 programs involve a different payer, which changes some of the statutes. The method is the same: identify the pharmacy, sort its orders, and follow the records to the people who generated them.
Can a telehealth company be liable for prescriptions its platform generates?
Yes. Federal law reaches anyone who aids, abets, or causes a violation under 18 U.S.C. § 2, and anyone who agrees to commit one under 18 U.S.C. § 371. The Empower letter places platform design inside the enforcement analysis by pointing to third-party technology platforms that give prescribers pre-selected menu options for significant difference statements.
The Done Global prosecution shows how DOJ uses platform design as evidence. The founder was sentenced to 72 months in July 2026 in a case built on the company's technology, compensation structure, and clinical protocols. For a GLP-1 platform, investigators examine who wrote the menu language, whether options were preselected, how prescribers were paid, how fast approvals occurred, and whether compliance staff raised concerns. HHS-OIG's 2022 Special Fraud Alert on telemedicine arrangements lists limited patient interaction and volume-based practitioner pay as suspect characteristics. FDA's March and June 2026 letters to telehealth companies are public, so later conduct will be measured against them.
Can a doctor or nurse practitioner be charged for templated GLP-1 prescriptions?
Yes, when the statement does not reflect the prescriber's own evaluation of the patient. Section 503A assigns the significant difference determination to the prescribing practitioner, so a selected template is legally the prescriber's clinical judgment. State medical and nursing boards treat inaccurate clinical attestations as professional misconduct.
Compounded GLP-1s are rarely covered by Medicare, but telehealth visits, lab work, and branded GLP-1 prescriptions often are billed to federal programs or commercial insurers. Where they are, false statements in the supporting record can support charges under 18 U.S.C. § 1347 or § 1035. Prescribers inside a coordinated scheme can be charged as conspirators or aiders and abettors in FDCA violations under 21 U.S.C. § 331. The government's proof in telehealth prescribing cases follows a pattern: approval volume, seconds per chart, per-prescription pay, and no follow-up care. A defense typically relies on a documented evaluation, a patient-specific reason for the compounded formulation, and platform data confirming independent judgment.
Does the Anti-Kickback Statute apply to cash-pay GLP-1 telehealth programs?
Often, at least in part. The federal Anti-Kickback Statute, 42 U.S.C. § 1320a-7b(b), applies to remuneration tied to items or services payable by a federal health care program. A cash-pay model narrows its reach. Pharmacies and platforms frequently carry some federal program business, though, and one payment arrangement can touch both.
Other laws apply regardless of payer. Many states have all-payer anti-kickback and fee-splitting statutes. The Travel Act, 18 U.S.C. § 1952, lets federal prosecutors charge schemes that violate state commercial bribery laws. Wire fraud reaches schemes that deceive patients or business partners. Investigators look for the same arrangements in every model: pharmacies paying platforms per prescription routed, platforms paying prescribers per approval, and affiliates paid on prescription volume. Whether each payment reflects fair market value for services actually performed is the central question in these cases.
Can a med spa legally sell compounded semaglutide or tirzepatide?
Yes, but only within the limits of Sections 503A and 503B, state pharmacy and medical practice law, and FDA labeling rules. A 503A pharmacy may compound only under valid prescriptions for identified individual patients, with a limited allowance for anticipatory compounding based on prescription history. Stocking 503A vials for office use, or supplying patient names after the fact to justify a bulk order, creates the problem DOJ alleged in its 2019 case against Guardian Pharmacy Services: drugs distributed without patient-specific prescriptions are misbranded and unapproved.
Med spas also inherit the significant difference issue when their prescribers use pre-written statements. FDA's 2026 telehealth letters add a labeling risk, because product branded with the seller's name implies the seller compounded it. Office-use supply from a registered 503B outsourcing facility follows different rules, with its own limits on copies. Armstrong & Bradylyons defends clinic owners, medical directors, and nurse injectors in these matters through its med spa and aesthetic medicine fraud defense practice.
Do clinical laboratories face exposure in GLP-1 telehealth programs?
Yes. Laboratories are often where federal and insurance dollars enter an otherwise cash-pay GLP-1 program. Many telehealth weight-loss programs order baseline or monitoring lab work, and those tests can be billed to Medicare, Medicaid, or commercial insurers even when the drug is not. Medicare generally requires diagnostic tests to be ordered by the physician or practitioner who treats the beneficiary and uses the results in the beneficiary's care. 42 CFR 410.32(a).
Tests ordered through a templated intake with no genuine treating relationship invite the medical necessity and false claims theories DOJ used in its telemedicine genetic testing cases. Referral payments carry separate risk. The Eliminating Kickbacks in Recovery Act, 18 U.S.C. § 220, applies to laboratories and reaches private insurers as well as federal programs. Per-test payments from a lab to a platform, marketer, or prescriber are the arrangement investigators examine first. Lab billing data also connects the lab to the same prescribers and platforms that appear in pharmacy records.
Can founders and executives be personally liable after an FDA warning letter?
Yes. Under the responsible corporate officer doctrine of United States v. Park, 421 U.S. 658 (1975), an executive with authority to prevent or correct an FDCA violation can be convicted of a misdemeanor under 21 U.S.C. § 333(a)(1) without proof of personal knowledge. Consent decrees in compounding cases routinely name owners individually. Felony liability under § 333(a)(2) requires intent to defraud or mislead, and courts have held that intent to mislead FDA can satisfy that element.
The government typically proves intent through prior notice. In Empower's case, FDA's April 2025 letter to the same facility went to the Director of Quality. The September 2026 letter, which repeats a sterility finding word for word, went to the founder and CEO. For telehealth startups, FDA's public March and June 2026 letters serve the same function. Board minutes, investor updates, and compliance escalations become evidence of what leadership knew and when.
Who defends compounding pharmacies, telehealth startups, and executives in GLP-1, peptide, and Anti-Kickback investigations?
Armstrong & Bradylyons PLLC, a Washington, D.C. firm founded by former senior DOJ fraud prosecutors, defends compounding pharmacies, outsourcing facilities, telehealth platforms, healthcare startups, med spas, prescribers, and executives in FDA warning letter and inspection matters, DOJ civil and criminal investigations, False Claims Act cases, and Anti-Kickback Statute investigations. The firm has represented executives at a leading peptides distributor in a DOJ investigation into research use only representations, executives in a joint DOJ and FDA-OCI investigation of a leading pharmaceutical company, healthcare startup founders and CEOs in DOJ investigations, and prescribers in DEA proceedings arising from a national testosterone clinic.
Scott Armstrong served as Director of DOJ's Appalachian Regional Prescription Opioid Strike Force and as an Assistant Chief in the Fraud Section, where he was lead counsel in a $126 million compounded medication fraud case. Drew Bradylyons served as an Assistant Chief supervising the Health Care Fraud Unit's Florida Strike Force, oversaw a nationwide telehealth DME enforcement action, and later served as Chief of the Financial Crimes and Public Corruption Unit in the Eastern District of Virginia. The firm's attorneys have tried 25 federal jury trials, including 17 healthcare fraud trials involving over $2.8 billion in alleged false claims. The work runs through the firm's peptide and GLP-1 fraud defense practice, and the firm handles matters nationwide.
